Accession Number : ADA624586


Title :   Developing a Novel Therapeutic Strategy Targeting Kallikrein-4 to Inhibit Prostate Cancer Growth and Metastasis


Descriptive Note : Annual rept. 31 Jul 2014-30 Jul 2015


Corporate Author : QUEENSLAND UNIV OF TECHNOLOGY BRISBANE (AUSTRALIA)


Personal Author(s) : Tse, Brian W


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a624586.pdf


Report Date : Aug 2015


Pagination or Media Count : 71


Abstract : Kallikrein-related peptidase 4 (KLK4) is a rational therapeutic target for prostate cancer (PCa) as it is up-regulated in both localised and bone metastatic tissue, and has been reported to increase PCa cell proliferation, induce epithelial-tomesenchymal (EMT)-like changes, and could have a role in PCa homing to bone. We therefore hypothesize that blockade of KLK4 activity will inhibit PCa growth and prevent metastasis to secondary sites like bone. This project aims to develop a novel therapeutic strategy targeting KLK4 specifically in PCa. KLK4 siRNA is incorporated into a novel polymeric-based drug-delivery platform currently in development by our laboratory (Queensland University of Technology)with collaborators from the Australian Institute of Bioengineering and Nanotechnology (AIBN), University of Queensland. In this drug-delivery system, the KLK4 siRNA is conjugated to a hyperbranched polymer (HBP) backbone, which is also attached at the periphery with a short peptide that binds to prostate specific membrane antigen (PSMA; expressed on 90% of PCa) for prostate-specific delivery of the therapeutic cargo.


Descriptors :   *METASTASIS , *PROSTATE CANCER , *THERAPY , ANTIGENS , BIOENGINEERING , BONES , CELLS(BIOLOGY) , GROWTH(PHYSIOLOGY) , LABORATORIES , MEMBRANES , NANOTECHNOLOGY , PEPTIDES , PLATFORMS , PROSTATE GLAND , SHORT RANGE(TIME) , TARGETING , TARGETS , TISSUES(BIOLOGY)


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE